Regulatory Reliance Pathways for Marketing Authorisation of Human Medicinal Products

The Tanzania Medicines and Medical Devices Authority (TMDA) has introduced comprehensive Guidelines on Regulatory Reliance for Marketing Authorisation of Human Medicinal Products, effective July 2025. This policy marks a significant shift in Tanzania's pharmaceutical regulatory landscape, aiming to streamline the market entry of safe, efficacious, and quality-assured medicines. By leveraging the scientific assessments and decisions of recognized stringent regulatory authorities and regional harmonization initiatives, the TMDA seeks to optimize its limited resources, reduce duplication of efforts, and accelerate patient access to essential medical products. The guidelines outline various reliance mechanisms, including abridged review, recognition, and work-sharing, presenting both opportunities for expedited approvals and specific compliance requirements for pharmaceutical companies and legal practitioners navigating the Tanzanian market.

The Tanzania Medicines and Medical Devices Authority (TMDA) has recently published its Guidelines on Regulatory Reliance for Marketing Authorisation of Human Medicinal Products, effective July 2025. This pivotal development signifies a strategic evolution in Tanzania's approach to pharmaceutical regulation, moving towards a more efficient and globally aligned system for granting marketing authorizations. The introduction of these reliance pathways is a direct response to the challenges faced by many national regulatory authorities, including resource constraints, the need to avoid duplicative assessments, and the imperative to facilitate timely access to quality medical products for the populace.

This initiative is poised to have a profound impact on pharmaceutical manufacturers, importers, and legal professionals operating within or seeking to enter the Tanzanian market. By formalizing mechanisms for leveraging the work of other trusted regulatory bodies, the TMDA aims to enhance regulatory efficiency and decision-making. This article will delve into the framework of these new reliance pathways, exploring their underlying legal and policy context, the specific mechanisms introduced, and the practical implications for practitioners advising clients on medicinal product registration in Tanzania.

The regulation of medicines, medical devices, and herbal drugs in Tanzania is primarily governed by the Tanzania Medicines and Medical Devices Act, Chapter 219 (Revised Edition of 2023). This Act establishes the TMDA as the principal body responsible for ensuring the safety, quality, and efficacy of medical products available in the country. Traditionally, the marketing authorization process in Tanzania, like in many other jurisdictions, involved a comprehensive and often lengthy de novo review of product dossiers, requiring significant time and resources from both the applicant and the regulatory authority.

Regulatory reliance, in the context of pharmaceutical regulation, is a principle whereby one regulatory authority considers and gives significant weight to the scientific assessments, decisions, or inspection outcomes performed by another trusted regulatory authority when making its own regulatory decisions. This approach is increasingly advocated by international bodies such as the World Health Organization (WHO) as a means to optimize limited regulatory resources, avoid redundant work, and expedite patient access to essential medical products. Across Africa, the adoption of reliance practices is gaining momentum, driven by initiatives like the African Medicines Agency (AMA) and various regional harmonization efforts, including the East African Community Medicines Regulatory Harmonisation (EAC-MRH) and the Southern Africa Development Community Medicines Regulatory Harmonisation (SADC-MRH), all aimed at overcoming fragmented regulatory landscapes and enhancing continental self-reliance in pharmaceuticals.

The TMDA's Guidelines on Regulatory Reliance for Marketing Authorisation of Human Medicinal Products introduce several distinct pathways designed to streamline the registration process. These mechanisms include standard process work sharing, abridged review, regional reliance, and unilateral and mutual recognition. The abridged review pathway, for instance, allows for a shortened assessment based on robust evidence that a medicinal product has undergone rigorous review and received a positive outcome from a Recognized Regulatory Authority (RRA). Similarly, the TMDA may expedite approval through the recognition of regulatory decisions made by other competent authorities, which can be unilateral or mutual, often guided by formal agreements.

Eligibility for these reliance pathways extends to new chemical entities and generic medicines that have been approved or registered by a range of recognized bodies. These include the TMDA itself, the African Medicines Agency (AMA), the European Medicines Agency (EMA), National Regulatory Authorities (NRAs) with WHO-Maturity Level 3/ML4, WHO Listed Authorities (WLAs), and regional harmonization initiatives such as EAC-MRH, IGAD, and SADC-MRH. A key benefit for applicants utilizing these pathways is the significantly reduced review timelines; applications submitted under the reliance pathway that meet the prescribed criteria are expected to receive an outcome within ninety (90) working days from the date of acceptance for review. This acceleration is crucial for improving patient access to safe, effective, and high-quality medicines, while also minimizing the duplication of regulatory efforts and optimizing the utilization of regulatory resources.

While the reliance pathways offer substantial advantages, practitioners must be cognizant of certain considerations. The TMDA emphasizes that while leveraging external assessments, it retains its independent responsibility and accountability for all regulatory decisions, thereby maintaining robust oversight standards. Applicants are required to provide a declaration letter for the sameness of the product dossier and highlight any new information acquired since the submission to the RRA. Furthermore, applications for variations of medicinal products initially registered through reliance procedures must include proof of approval for such changes from the RRA. This approach is consistent with global best practices and similar to the South African Health Products Regulatory Authority (SAHPRA)'s implementation of abridged review processes to manage backlogs and enhance efficiency, demonstrating a regional trend towards smarter regulation.

The TMDA's formalization of regulatory reliance pathways represents a progressive and pragmatic step towards modernizing pharmaceutical regulation in Tanzania. By embracing international best practices and regional harmonization efforts, the Authority is poised to enhance efficiency, optimize resources, and, most importantly, facilitate faster access to essential medicines for its population. This strategic shift creates a more predictable and expedited route to market for pharmaceutical products, aligning Tanzania with a global movement towards collaborative regulatory oversight.

For legal practitioners and pharmaceutical companies, understanding and strategically utilizing these new guidelines is paramount. It necessitates a thorough review of the eligibility criteria, the specific documentation requirements for each reliance pathway, and the ongoing obligations for post-market surveillance and variations. Practitioners should advise clients on preparing comprehensive applications that clearly demonstrate prior approval by recognized authorities and address any local specificities, such as labelling and pharmacovigilance. As the TMDA continues to strengthen its regulatory systems, stakeholders should remain engaged with evolving policies to fully leverage the opportunities presented by these reliance pathways, contributing to a more robust and responsive healthcare landscape in Tanzania.